{"id":"https://openalex.org/W3118792002","doi":"https://doi.org/10.1093/ofid/ofaa439.1673","title":"1492. Targeted Substitution of Omadacycline in Place of Standard of Care for CABP Treatment is Associated with a Risk Reduction of Clostridioides difficile Infection and Financial Cost Savings in the Acute Care Setting","display_name":"1492. Targeted Substitution of Omadacycline in Place of Standard of Care for CABP Treatment is Associated with a Risk Reduction of Clostridioides difficile Infection and Financial Cost Savings in the Acute Care Setting","publication_year":2020,"publication_date":"2020-10-01","ids":{"openalex":"https://openalex.org/W3118792002","doi":"https://doi.org/10.1093/ofid/ofaa439.1673","mag":"3118792002","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/7777690"},"language":"en","primary_location":{"id":"doi:10.1093/ofid/ofaa439.1673","doi":"https://doi.org/10.1093/ofid/ofaa439.1673","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ofid/ofaa439.1673","pdf_url":"https://academic.oup.com/ofid/article-pdf/7/Supplement_1/S747/35343553/ofaa439.1673.pdf","source":{"id":"https://openalex.org/S2735126445","display_name":"Open Forum Infectious Diseases","issn_l":"2328-8957","issn":["2328-8957"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infectious Diseases","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://academic.oup.com/ofid/article-pdf/7/Supplement_1/S747/35343553/ofaa439.1673.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5109418963","display_name":"Mauricio Rodr\u00edguez","orcid":"https://orcid.org/0000-0002-4334-6760","observed_orcids":["https://orcid.org/0000-0002-4334-6760"]},"institutions":[{"id":"https://openalex.org/I4210101063","display_name":"Paratek Pharmaceuticals (United States)","ror":"https://ror.org/019g7bh20","country_code":"US","type":"company","lineage":["https://openalex.org/I4210101063"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mauricio Rodriguez","raw_affiliation_strings":["Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania","institution_ids":["https://openalex.org/I4210101063"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062874736","display_name":"Surya Chitra","orcid":"https://orcid.org/0000-0002-5682-9200","observed_orcids":["https://orcid.org/0000-0002-5682-9200"]},"institutions":[{"id":"https://openalex.org/I4210101063","display_name":"Paratek Pharmaceuticals (United States)","ror":"https://ror.org/019g7bh20","country_code":"US","type":"company","lineage":["https://openalex.org/I4210101063"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Surya Chitra","raw_affiliation_strings":["Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania","institution_ids":["https://openalex.org/I4210101063"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072370749","display_name":"Kelly Wright","orcid":"https://orcid.org/0000-0003-2908-2612","observed_orcids":["https://orcid.org/0000-0003-2908-2612"]},"institutions":[{"id":"https://openalex.org/I4210101063","display_name":"Paratek Pharmaceuticals (United States)","ror":"https://ror.org/019g7bh20","country_code":"US","type":"company","lineage":["https://openalex.org/I4210101063"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kelly Wright","raw_affiliation_strings":["Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania","institution_ids":["https://openalex.org/I4210101063"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5084249121","display_name":"Thomas P. Lodise","orcid":"https://orcid.org/0000-0002-4730-0655","observed_orcids":["https://orcid.org/0000-0002-4730-0655"]},"institutions":[{"id":"https://openalex.org/I365282","display_name":"Albany College of Pharmacy and Health Sciences","ror":"https://ror.org/014hfaw95","country_code":"US","type":"education","lineage":["https://openalex.org/I365282"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas Lodise","raw_affiliation_strings":["Albany College of Pharmacy and Health Sciences, Albany, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Albany College of Pharmacy and Health Sciences, Albany, NY","institution_ids":["https://openalex.org/I365282"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4053,"currency":"USD","value_usd":4053},"apc_paid":{"value":4053,"currency":"USD","value_usd":4053},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"7","issue":"Supplement_1","first_page":"S747","last_page":"S748"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11288","display_name":"Clostridium difficile and Clostridium perfringens research","score":0.8812999725341797,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11288","display_name":"Clostridium difficile and Clostridium perfringens research","score":0.8812999725341797,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10654","display_name":"Pneumonia and Respiratory Infections","score":0.06509999930858612,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.014600000344216824,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/omadacycline","display_name":"omadacycline","score":0.9890000224113464},{"id":"https://openalex.org/keywords/community-acquired-bacterial-pneumonia","display_name":"community-acquired bacterial pneumonia","score":0.9309999942779541},{"id":"https://openalex.org/keywords/clostridium-difficile-infection","display_name":"Clostridium difficile infection","score":0.9950000047683716},{"id":"https://openalex.org/keywords/antibiotic-alternatives","display_name":"antibiotic alternatives","score":0.4230000078678131},{"id":"https://openalex.org/keywords/fluoroquinolones","display_name":"fluoroquinolones","score":0.7670000195503235},{"id":"https://openalex.org/keywords/ceftriaxone","display_name":"ceftriaxone","score":0.9940000176429749},{"id":"https://openalex.org/keywords/healthcare-cost-reduction","display_name":"healthcare cost reduction","score":0.656000018119812},{"id":"https://openalex.org/keywords/economic-impact","display_name":"economic impact","score":0.5289999842643738},{"id":"https://openalex.org/keywords/length-of-hospital-stay","display_name":"length of hospital stay","score":0.6389999985694885},{"id":"https://openalex.org/keywords/recurrent-clostridioides-difficile-infection","display_name":"recurrent Clostridium difficile infection","score":0.49799999594688416},{"id":"https://openalex.org/keywords/decision-analytic-model","display_name":"decision-analytic model","score":0.515999972820282},{"id":"https://openalex.org/keywords/hospitalized-patients","display_name":"hospitalized patients","score":0.5809999704360962},{"id":"https://openalex.org/keywords/moxifloxacin","display_name":"moxifloxacin","score":0.7149999737739563},{"id":"https://openalex.org/keywords/acute-care-settings","display_name":"acute care settings","score":0.45899999141693115}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8825579285621643},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5806811451911926},{"id":"https://openalex.org/C2776102371","wikidata":"https://www.wikidata.org/wiki/Q460030","display_name":"Community-acquired pneumonia","level":3,"score":0.5804904699325562},{"id":"https://openalex.org/C2777914695","wikidata":"https://www.wikidata.org/wiki/Q12192","display_name":"Pneumonia","level":2,"score":0.4731360971927643},{"id":"https://openalex.org/C2778836808","wikidata":"https://www.wikidata.org/wiki/Q424940","display_name":"Moxifloxacin","level":3,"score":0.44970792531967163},{"id":"https://openalex.org/C501593827","wikidata":"https://www.wikidata.org/wiki/Q12187","display_name":"Antibiotics","level":2,"score":0.278766930103302},{"id":"https://openalex.org/C89423630","wikidata":"https://www.wikidata.org/wiki/Q7193","display_name":"Microbiology","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1093/ofid/ofaa439.1673","doi":"https://doi.org/10.1093/ofid/ofaa439.1673","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ofid/ofaa439.1673","pdf_url":"https://academic.oup.com/ofid/article-pdf/7/Supplement_1/S747/35343553/ofaa439.1673.pdf","source":{"id":"https://openalex.org/S2735126445","display_name":"Open Forum Infectious Diseases","issn_l":"2328-8957","issn":["2328-8957"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infectious Diseases","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:6698453","doi":null,"is_oa":true,"landing_page_url":"http://europepmc.org/pmc/articles/PMC7777690","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"","raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:7777690","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7777690/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infect Dis","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1093/ofid/ofaa439.1673","doi":"https://doi.org/10.1093/ofid/ofaa439.1673","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ofid/ofaa439.1673","pdf_url":"https://academic.oup.com/ofid/article-pdf/7/Supplement_1/S747/35343553/ofaa439.1673.pdf","source":{"id":"https://openalex.org/S2735126445","display_name":"Open Forum Infectious Diseases","issn_l":"2328-8957","issn":["2328-8957"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infectious Diseases","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3118792002.pdf","grobid_xml":"https://content.openalex.org/works/W3118792002.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3204245368","https://openalex.org/W3131297308","https://openalex.org/W4281749488","https://openalex.org/W2896590978","https://openalex.org/W2920865212","https://openalex.org/W2966148030","https://openalex.org/W4311743290","https://openalex.org/W7203780114","https://openalex.org/W3027716121","https://openalex.org/W2745806880"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"Real-world":[2],"evidence":[3],"studies":[4],"indicate":[5],"that":[6],"around":[7],"3%":[8],"of":[9,59,85,107,131,180,213,222,248,253,257,263,267,272,291,302,326,342],"hospitalized":[10,142,349],"patients":[11,87,109,144,182,191,237,279,329],"with":[12,29,42,110,139,145,165,183,192,196,238,245,280,304,351],"community-acquired":[13,60],"pneumonia":[14,62],"(CAP)":[15],"develop":[16],"Clostridioides":[17],"difficile":[18],"infection":[19],"(CDI;":[20],"Chalmers":[21],"et":[22,99],"al,":[23,100],"J":[24,103],"Infect":[25],"2016;73:45\u201353).":[26],"Factors":[27],"associated":[28,164,378],"increased":[30],"CDI":[31,72,93,115,187,200,220,241,300,307,331,360,375],"risk":[32,35,188,221,301,310,332],"include":[33],"Davis":[34],"score":[36],"(DRS)":[37],"\u2265":[38,112,147,185,194,282,354],"6,":[39,186],"and":[40,49,64,75,137,203,205,211,377],"treatment":[41,58,135,167],"high-risk":[43,327],"antibiotics":[44,328],"such":[45],"as":[46,231,366],"fluroquinolones":[47],"(FQ)":[48],"ceftriaxone":[50],"(CTX).":[51],"Omadacycline":[52],"(OMC)":[53],"is":[54,308,322],"indicated":[55],"for":[56,96,141,189,226,265,274,295,369],"the":[57,79,119,128,275],"bacterial":[61],"(CABP)":[63],"has":[65],"demonstrated":[66],"a":[67,287,309,352,367],"low":[68],"propensity":[69],"to":[70,217,293,372],"induce":[71],"in":[73,118,177,286,324,348],"preclinical":[74],"clinical":[76],"studies.":[77],"In":[78],"phase":[80],"3":[81],"OPTIC":[82],"study,":[83],"2%":[84],"CABP":[86,134,143,198,278,346,350],"who":[88],"received":[89],"moxifloxacin":[90],"(MOX)":[91],"developed":[92,114],"vs":[94,116],"0%":[95,117,223,303],"OMC":[97,120,140,206,268,273,321],"(Stets":[98],"N":[101],"Engl":[102],"Med":[104],"2019;380:517\u201327);":[105],"14%":[106],"MOX":[108],"DRS":[111,146,184,193,281,353],"6":[113,195,283,355],"group":[121],"(Table":[122,208],"1;":[123],"Figure":[124,151],"1).":[125],"We":[126],"assessed":[127],"economic":[129],"impact":[130],"substituting":[132],"current":[133,197,345],"(FQ":[136],"CTX)":[138],"6.":[148],"Table":[149,233],"1":[150,152],"Methods":[153],"A":[154],"deterministic":[155],"healthcare-decision":[156],"analytic":[157],"model":[158,171],"was":[159,224,269],"performed.":[160],"Only":[161],"excess":[162],"costs":[163,201,242,247,252],"each":[166],"were":[168,215,243],"considered.":[169],"Base-case":[170],"inputs":[172],"were:":[173],"yearly":[174],"CAP":[175,181,190],"admission":[176],"US,":[178],"prevalence":[179],"treatments,":[199],"(initial":[202],"recurrent),":[204],"cost":[207,256,289,315],"2).":[209],"Efficacy":[210],"safety":[212],"treatments":[214,347],"assumed":[216,225],"be":[218,318],"equal.":[219],"OMC.":[227,305],"Costs":[228],"are":[229],"reported":[230],"USD.":[232],"2":[234],"Results":[235],"For":[236],"CABP,":[239],"total":[240],"$738M,":[244],"first-episode":[246],"$489M":[249],"plus":[250],"recurrence":[251],"$249M.":[254],"The":[255],"5":[258],"days":[259],"(mean":[260],"hospital":[261,374],"length":[262],"stay":[264],"CABP)":[266],"$207M.":[270],"Use":[271],"estimated":[276],"100,000":[277],"would":[284],"result":[285],"potential":[288],"saving":[290],"up":[292],"$531M":[294],"this":[296],"patient":[297],"population,":[298],"assuming":[299],"As":[306],"from":[311],"any":[312],"antibiotic":[313],"use,":[314],"savings":[316],"can":[317,364],"achieved":[319],"when":[320,330],"used":[323],"place":[325],"rates":[333,376],"exceed":[334],"3.9%.":[335],"Conclusion":[336],"Our":[337],"findings":[338],"suggest":[339],"prioritizing":[340],"use":[341],"omadacycline":[343],"over":[344],"may":[356],"substantially":[357],"reduce":[358,373],"attributable":[359],"costs.":[361,379],"These":[362],"results":[363],"serve":[365],"basis":[368],"stewardship":[370],"interventions":[371],"Disclosures":[380],"Mauricio":[381],"Rodriguez,":[382],"PharmD,":[383,400,408],"BCPS,":[384],"BCCCP,":[385],"BCIDP,":[386],"Paratek":[387,394,401,410],"Pharmaceuticals,":[388,395,402,411],"Inc.":[389,396,403,412],"(Employee)":[390],"Surya":[391],"Chitra,":[392],"PhD,":[393,409],"(Consultant)":[397,413],"Kelly":[398],"Wright,":[399],"(Employee,":[404],"Shareholder)":[405],"Thomas":[406],"Lodise,":[407]},"counts_by_year":[],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2021-01-18T00:00:00"}